Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 88.07% is in line with its 5-year average of 87.47%, near the high end of its 5-year range (82.29%–90.13%).
0.47% below its 12-month average of 88.49%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 84.63%.
GROSS MARGIN
88.07%
GROSS MARGIN AVG TTM
88.49%
GROSS MARGIN AVG 3Y
88.05%
GROSS MARGIN AVG 5Y
87.47%
GROSS MARGIN AVG 10Y
90.68%
GROSS MARGIN AVG 15Y
92.70%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.47%
CURRENT VS 3Y AVG
+0.02%
CURRENT VS 5Y AVG
+0.69%
CURRENT VS 10Y AVG
-2.88%
CURRENT VS 15Y AVG
-4.99%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+112.83%
vs the sector median at left
Supernus Pharmaceuticals, Inc.
Market Cap
$2.45B
Gross Margin
88.07%
TTM Avg
88.49%
3Y Avg
88.05%
5Y Avg
87.47%
Market Cap
$2.40B
Gross Margin
18.57%
TTM Avg
22.55%
3Y Avg
18.71%
5Y Avg
13.63%
Market Cap
$2.40B
Gross Margin
-61.96%
TTM Avg
-19.42%
3Y Avg
-14.39%
5Y Avg
23.74%
Market Cap
$2.52B
Gross Margin
92.15%
TTM Avg
99.87%
3Y Avg
99.94%
5Y Avg
66.62%
Market Cap
$2.37B
Gross Margin
56.20%
TTM Avg
28.10%
3Y Avg
28.10%
5Y Avg
28.10%
Market Cap
$2.36B
Gross Margin
64.71%
TTM Avg
54.44%
3Y Avg
41.55%
5Y Avg
20.41%
Market Cap
$2.34B
Gross Margin
77.55%
TTM Avg
-114.38%
3Y Avg
-188.02%
5Y Avg
-219.43%
Market Cap
$2.35B
Gross Margin
92.48%
TTM Avg
74.82%
3Y Avg
78.80%
5Y Avg
76.59%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | $2.45B | 88.07% | 88.49% | 88.05% | 87.47% |
| Disc Medicine, Inc. (IRON)vs › | $2.42B | 0.00% | 0.00% | 0.00% | 0.00% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | 18.57% | 22.55% | 18.71% | 13.63% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | -61.96% | -19.42% | -14.39% | 23.74% |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.52B | 92.15% | 99.87% | 99.94% | 66.62% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.37B | 56.20% | 28.10% | 28.10% | 28.10% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 64.71% | 54.44% | 41.55% | 20.41% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.34B | 77.55% | -114.38% | -188.02% | -219.43% |
| Liquidia Corporation (LQDA)vs › | $2.35B | 92.48% | 74.82% | 78.80% | 76.59% |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 28.50% | 28.67% | 27.73% | 26.77% |
Gross Margin
88.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 84.63% |
| 2026-03-31 | 88.74% |
| 2025-12-31 | 89.13% |
| 2025-09-30 | 90.13% |
| 2025-06-30 | 89.83% |
| 2025-03-31 | 89.48% |
| 2024-12-31 | 85.01% |
| 2024-09-30 | 89.99% |
| 2024-06-30 | 89.36% |
| 2024-03-31 | 88.65% |
| 2023-12-31 | 88.06% |
| 2023-09-30 | 87.26% |
| 2023-06-30 | 84.44% |
| 2023-03-31 | 84.74% |
| 2022-12-31 | 86.28% |
| 2022-09-30 | 85.41% |
| 2022-06-30 | 87.97% |
| 2022-03-31 | 88.24% |
| 2021-12-31 | 89.32% |
| 2021-09-30 | 87.82% |
| 2021-06-30 | 82.29% |
| 2021-03-31 | 88.58% |
| 2020-12-31 | 87.09% |
| 2020-09-30 | 86.21% |
| 2020-06-30 | 93.38% |
| 2020-03-31 | 95.63% |
| 2019-12-31 | 95.91% |
| 2019-09-30 | 95.28% |
| 2019-06-30 | 96.14% |
| 2019-03-31 | 95.69% |
| 2018-12-31 | 96.39% |
| 2018-09-30 | 95.92% |
| 2018-06-30 | 96.30% |
| 2018-03-31 | 96.38% |
| 2017-12-31 | 95.30% |
| 2017-09-30 | 94.71% |
| 2017-06-30 | 94.91% |
| 2017-03-31 | 94.88% |
| 2016-12-31 | 93.95% |
| 2016-09-30 | 93.97% |
| 2016-06-30 | 94.54% |
| 2016-03-31 | 95.28% |
| 2015-12-31 | 93.45% |
| 2015-09-30 | 94.17% |
| 2015-06-30 | 94.97% |
| 2015-03-31 | 94.25% |
| 2014-12-31 | 92.59% |
| 2014-09-30 | 97.48% |
| 2014-06-30 | 94.40% |
| 2014-03-31 | 94.56% |
| 2013-12-31 | 89.68% |
| 2013-09-30 | 97.37% |
| 2013-06-30 | 98.58% |
| 2013-03-31 | 100.00% |
| 2012-12-31 | 100.00% |
| 2012-09-30 | 100.00% |
| 2012-06-30 | 100.00% |
| 2012-03-31 | 100.00% |
| 2011-12-31 | 100.00% |
| 2011-09-30 | 100.00% |
| 2011-06-30 | 100.00% |
| 2011-03-31 | 0.00% |
| 2010-12-31 | -55.39% |
| 2010-09-30 | 0.00% |
| 2009-12-31 | -67.10% |
